NCT06106308Phase 2Active not recruiting

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-11Estimated

Enrollment · participants110Actual

Source updated2026-06-16Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-16 · 1 field changed

Actual enrollment decreased by 3 participants

− Before

~~113 participants (actual)~~

+ After

110 participants (actual)

Check registry source

Study details

Conditions studied

Metastatic Colorectal Cancer; CRC; KRAS/NRAS Mutation

Treatments or interventions studied

OnvansertibDrug
FOLFIRIDrug
BevacizumabDrug
FOLFOXDrug

Primary outcomes · main study measures

measure: Objective Response Rate (ORR); description: ORR defined as the proportion of participants who achieved a best overall Response (BOR) of CR or PR per RECIST Version 1.1 from randomization until disease progression, or death due to any cause, as determined by blinded independent central review.; timeFrame: Up to approximately 1 year

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history